NXTC NextCure (NXTC) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001661059
SEC filings
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
19
13F, latest reported quarter
What the filings say about NXTC
Insiders, 180 days
+$1.4M net bought
1 buyer · 1 seller · 0% of sales under a 10b5-1 plan
NextCure insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, NextCure, Inc. insiders bought a net $1.4M of stock across 16 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 14 earlier Form 4 trades (code P or S) here by this insider (14 buys), the last on Oct 26, 2026.
- The trade is 0.5% of the 733,270 shares held after it.
- No other insider bought within 30 days.
- 19 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider ADAR1 Capital Management, LLC bought about $18.1K of NXTC on Oct 27, 2026; 19 funds added in the latest 13F quarter.Context
- 13 earlier Form 4 trades (code P or S) here by this insider (13 buys), the last on Oct 23, 2026.
- The trade is 0.2% of the 729,717 shares held after it.
- No other insider bought within 30 days.
- 19 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider ADAR1 Capital Management, LLC bought about $8.4K of NXTC on Oct 26, 2026; 19 funds added in the latest 13F quarter.Context
- 12 earlier Form 4 trades (code P or S) here by this insider (12 buys), the last on Jul 31, 2026.
- The trade is 0.8% of the 728,045 shares held after it.
- No other insider bought within 30 days.
- 19 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider ADAR1 Capital Management, LLC bought about $27.2K of NXTC on Oct 23, 2026; 19 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 9.7% of the 308,636 shares held after it.
- No other insider sold within 30 days.
- 19 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Simcere Zaiming, Inc. sold about $184.8K of NXTC on Aug 10, 2026, the largest insider sale at the company on our record; 19 funds added in the latest 13F quarter.Context
- 9 earlier Form 4 trades (code P or S) here by this insider (9 buys), the last on Jul 30, 2026.
- The trade is 0.5% of the 689,416 shares held after it.
- No other insider bought within 30 days.
- 19 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider ADAR1 Capital Management, LLC bought about $16.4K of NXTC on Jul 31, 2026; 19 funds added in the latest 13F quarter.16 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$1.4M over 180 days
+$1.4M over 90 days · +$1.6M of it by a 10%+ holder
more than 91% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
19 funds bought in last quarter
below 70% of Pharma & Biotech
Revenue
+252.6% year over year
more than 90% of Pharma & Biotech
Margin
-249.5% net margin
below 69% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
7.3% of the float short (float per yahoo 2026-10-26) · 1.9 days to cover · settled 2026-09-30
below 51% of Pharma & Biotech
What changed in the last 30 days
Oct 27Insider ADAR1 Capital Management, LLC bought $53.7K (3 trades, Oct 23 to Oct 27)
Watch NXTC
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-44.0%12M
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns NXTC: institutional holders (13F)
13F holdings, latest reported quarter
288,303 sh
$461.3K
277,202 sh
$443.5K
222,654 sh
$356.2K
171,202 sh
$273.9K
156,842 sh
$250.9K
Congress trades in NXTC
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
NXTC planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
NXTC mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ultra-Small Company Market Fund
$4.8K position · as of 2026-06-30
0.0%
Nomura Healthcare Fund
$20.0K position · as of 2026-06-30
0.0%
iShares Micro-Cap ETF
$15.8K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$1.2K position · as of 2026-06-30
0.0%
Fidelity Extended Market Index Fund
$100.8K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$53.7K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
7 registered trials, 2 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
3
Phase 1
2 active
4
Multi-phase
0 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $1.4M bought by insiders over 180 days, 19 funds added last quarter. Each figure is a federal filing, dated the day it went public.
NXTC financials
Revenue growth
+252.6%
XBRL, annual
Net margin
-249.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$22.4M
four quarters, 2020-01-01 to 2020-12-31
Revenue, TTM NXTC
| FY Dec 2025 | $22.4M |
| FY Dec 2024 | $22.4M |
| FY Dec 2023 | $22.4M |
| FY Dec 2022 | $22.4M |
| FY Dec 2021 | $22.4M |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Net margin, TTM
-191.0%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM NXTC
| FY Dec 2025 | -249.5% |
| FY Dec 2024 | -248.7% |
| FY Dec 2023 | -280.3% |
| FY Dec 2022 | -334.0% |
| FY Dec 2021 | -310.1% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$37.5M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM NXTC
| FY Dec 2025 | -$50.1M |
| FY Dec 2024 | -$41.3M |
| FY Dec 2023 | -$53.8M |
| FY Dec 2022 | -$56.0M |
| FY Dec 2021 | -$59.6M |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | -$6.9M |
| Sep 2024 | -$11.6M |
At each fiscal year end
Single quarter
Debt to equity
0.00x
LongTermDebt as filed 2022-12-31 (42 months older than the period end) (includes the current portion); equity 2026-06-30
Debt to equity NXTC
| FY Dec 2025 | 0.00x |
| FY Dec 2024 | 0.00x |
| FY Dec 2023 | 0.00x |
| FY Dec 2022 | 0.00x |
| FY Dec 2021 | 0.00x |
| Jun 2026 | 0.00x |
| Mar 2026 | 0.00x |
| Dec 2025 | 0.00x |
| Sep 2025 | 0.00x |
| Jun 2025 | 0.00x |
| Mar 2025 | 0.00x |
| Dec 2024 | 0.00x |
| Sep 2024 | 0.00x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt to cover
Cash flow to debt NXTC
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-204.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity NXTC
| FY Dec 2025 | -111.2% |
| FY Dec 2024 | -61.9% |
| FY Dec 2023 | -44.5% |
| FY Dec 2022 | -37.3% |
| FY Dec 2021 | -26.3% |
| Jun 2026 | -204.6% |
| Mar 2026 | -132.4% |
| Dec 2025 | -111.2% |
| Sep 2025 | -116.9% |
| Jun 2025 | -105.9% |
| Mar 2025 | -63.9% |
| Dec 2024 | -61.9% |
| Sep 2024 | -57.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-121.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets NXTC
| FY Dec 2025 | -85.2% |
| FY Dec 2024 | -53.3% |
| FY Dec 2023 | -40.2% |
| FY Dec 2022 | -35.0% |
| FY Dec 2021 | -25.3% |
| Jun 2026 | -121.6% |
| Mar 2026 | -104.0% |
| Dec 2025 | -85.2% |
| Sep 2025 | -89.3% |
| Jun 2025 | -81.1% |
| Mar 2025 | -54.3% |
| Dec 2024 | -53.3% |
| Sep 2024 | -50.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital NXTC
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-165.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed NXTC
| FY Dec 2025 | -103.9% |
| FY Dec 2024 | -62.1% |
| FY Dec 2023 | -45.7% |
| FY Dec 2022 | -37.0% |
| FY Dec 2021 | -26.6% |
| Jun 2026 | -165.3% |
| Mar 2026 | -121.3% |
| Dec 2025 | -103.9% |
| Sep 2025 | -109.4% |
| Jun 2025 | -99.3% |
| Mar 2025 | -63.6% |
| Dec 2024 | -62.1% |
| Sep 2024 | -58.7% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing NXTC
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$7.5M
market value at close 2026-10-23 on 2026-07-31 shares, plus LongTermDebt as filed 2022-12-31 (42 months older than the period end) (includes the current portion), minus cash 2026-06-30
Enterprise value NXTC
| FY Dec 2025 | $12.0M |
| FY Dec 2024 | $231.4M |
| FY Dec 2023 | $368.6M |
| FY Dec 2022 | $443.3M |
| FY Dec 2021 | $2.0B |
| Jun 2026 | -$9.5M |
| Mar 2026 | $22.9M |
| Dec 2025 | $12.0M |
| Sep 2025 | $8.4M |
| Jun 2025 | $149.9M |
| Mar 2025 | $139.5M |
| Dec 2024 | $231.4M |
| Sep 2024 | $432.2M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-164.3%
TTM free cash flow over market value at close 2026-10-23
FCF yield NXTC
| FY Dec 2025 | -131.7% |
| FY Dec 2024 | -15.9% |
| FY Dec 2023 | -14.1% |
| FY Dec 2022 | -11.9% |
| FY Dec 2021 | -3.0% |
| Jun 2026 | -648.1% |
| Mar 2026 | -132.7% |
| Dec 2025 | -131.7% |
| Sep 2025 | -315.1% |
| Jun 2025 | -35.3% |
| Mar 2025 | -25.8% |
| Dec 2024 | -15.9% |
| Sep 2024 | -9.8% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing NXTC
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Operating income | -$57.6M | -$59.7M | -$67.6M | -$75.9M |
| Net income | -$55.8M | -$55.7M | -$62.7M | -$74.7M |
| EPS (diluted) | -19.65 | -23.88 | -2.25 | -2.69 |
| Operating cash flow | -$49.6M | -$40.8M | -$53.0M | -$53.9M |
| Cash | $26.0M | $27.7M | $13.1M | $26.6M |
| Long-term debt | n/a | n/a | n/a | $0 |
SEC XBRL, fiscal years, as known on 2026-10-28
NXTC Stock Sonar score 6/7 axes
Find similar shapesCompareNXTC ranks highest on financial health (99th percentile) and growth (90th), and lowest on profitability (17th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
NXTC filings, in plain words
Are NextCure insiders buying or selling NXTC?
In the 180 days to 2026-10-28, NextCure insiders were net buyers, a net $1.4M: $1.6M of purchases and $184.8K of sales reported on Form 4, by 1 buyer and 1 seller.
Read the full summary
In the 180 days to 2026-10-28, NextCure insiders were net buyers of NXTC, a net $1.4M across purchases and sales reported on Form 4 by 1 buyer and 1 seller. Most of that figure, $1.6M, came from a holder of 10% or more rather than an officer or director. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
